How Accurate Is a Fecal Occult Blood Immunoassay?

A fecal occult blood immunoassay, widely known as FIT (fecal immunochemical test), is a stool-based screening tool that uses antibodies to detect tiny amounts of human hemoglobin in feces, serving as an early warning sign of colorectal cancer or precancerous growths. Unlike the older guaiac-based stool tests, FIT zeroes in on human blood specifically, which means you don’t need to restrict your diet before the test. A single FIT catches roughly 90 percent of colorectal cancers when the test threshold is set low enough, and population-level screening programs have shown meaningful drops in colorectal cancer deaths. Still, the test’s performance depends on details that most people never hear about, from the cutoff number your lab uses to how warm the sample gets before it reaches the analyzer.

Why FIT Replaced the Old Guaiac Test

For decades, colorectal cancer screening by stool test meant smearing a sample on a card treated with guaiac resin, which changes color when any heme (the iron-containing part of hemoglobin) is present. The problem is that heme shows up in red meat, certain vegetables, and animal blood in food, so patients had to follow dietary restrictions for days before collection. FIT sidesteps all of that because the antibodies it uses are specific to human hemoglobin. Testing has confirmed no cross-reactivity with non-human hemoglobins from common dietary sources, eliminating the need for pre-test food rules.¹ That specificity also means FIT is better at flagging bleeding from the lower gut, where colorectal tumors tend to be, because hemoglobin from upper gastrointestinal sources is partly digested and less recognizable to the antibodies by the time it reaches the colon.

The switch from guaiac to FIT also boosted how many people actually complete the screening. A meta-analysis found that participation was about 21 percent higher when people were offered FIT instead of the guaiac test.² A U.S. outreach program saw stool-test completion jump from about 28 percent in the guaiac era to 37 percent after switching to FIT.³ The reasons are straightforward: FIT requires only one sample instead of three, needs no dietary prep, and uses a simpler collection device. In populations given FIT as the sole stool option, acceptance rates have reached the mid-90s, far outpacing colonoscopy uptake in the same programs.⁴

How Accurately FIT Detects Cancer and Precancerous Growths

For a screening test, two numbers matter most: sensitivity (how often it correctly flags a real cancer) and specificity (how often it correctly leaves healthy people alone). A large systematic review and meta-analysis looked at FIT performance across many studies and found that at a low threshold of 10 micrograms of hemoglobin per gram of feces, sensitivity for colorectal cancer was about 91 percent, with a specificity around 90 percent. Raising the threshold above 20 micrograms pushed specificity up to about 95 percent, though at the cost of missing slightly more cancers.⁵

The picture is less rosy for advanced precancerous polyps (called advanced adenomas). Even at the most sensitive threshold, FIT picks up only about 40 percent of these growths in a single round of testing.⁶ That sounds alarming, but the logic of repeat screening helps: precancerous polyps grow slowly, and a polyp missed this year may bleed enough to be caught in the next annual or biennial round. FIT is designed as a test you repeat on schedule, not a one-and-done exam.

The Cutoff Number That Shapes Everything

FIT is quantitative, meaning the analyzer spits out an actual hemoglobin concentration rather than just a positive or negative. The screening program then applies a cutoff: results above that number count as positive and get a follow-up colonoscopy. This cutoff is arguably the most important variable in the entire process, because it determines how many cancers get caught, how many healthy people get unnecessary colonoscopies, and how much the program costs.

A community-based cohort study illustrates the trade-off clearly. At a threshold of 10 micrograms per gram, about 79 percent of cancers were detected over the study period, but the program needed 85 positive tests for every cancer found. Raising the cutoff to 20 caught about 74 percent, needing 52 positive tests per cancer. At 30, detection fell to 66 percent with 43 positives per cancer case. The jump from 20 down to 15 would catch only 3 percent more cancers but require 23 percent more colonoscopies.⁷

In a modeling exercise on a hypothetical population of 100,000 people, the lowest threshold studied (8.5 micrograms per gram) caught 98 percent of cancers but demanded over 17,500 colonoscopies, more than 12,000 of which found nothing. The highest threshold (120 micrograms per gram) missed nearly half of all cancers but needed only about 2,600 colonoscopies.⁸ Different countries land at very different numbers. An international survey found that nine programs had adjusted their thresholds since launch: three lowered them to catch more cancers, while six raised them to manage colonoscopy demand, including four Spanish regions that pushed thresholds up during the pandemic when endoscopy capacity shrank.⁹

One source of confusion is that different FIT brands report results in different units, which makes it hard to compare programs across countries or even across labs in the same city. A widely cited proposal recommended that all manufacturers and researchers express results as micrograms of hemoglobin per gram of feces, with transparent documentation of the fecal mass sampled and buffer volume used.¹⁰ Adoption has been growing, but non-standardized units still circulate, so if you see a FIT result, make sure you know what scale your lab is using before comparing it to published thresholds.

What Causes False Positives

A positive FIT doesn’t always mean cancer or even a polyp. Any source of bleeding in the lower gastrointestinal tract can raise the hemoglobin level in stool. Hemorrhoids are among the most common culprits. A study of over 3,500 screening participants found that people with hemorrhoids were roughly 2.8 times more likely to have a false-positive FIT than those without.¹¹

A large study of nearly 25,000 asymptomatic screening participants found that older age, female sex, smoking, alcohol consumption, higher body weight, hemorrhoids, and diverticular disease were all associated with increased false-positive odds. On the flip side, some of those same factors (older age, hemorrhoids) were also linked to lower false-negative rates, suggesting that the additional bleeding, while nonspecific, helps the test catch real lesions too.¹² Colorectal inflammation and the presence of multiple small, non-advanced polyps can also push a result above the cutoff without advanced neoplasia being present.¹³

Aspirin, Blood Thinners, and FIT Results

A common concern is whether taking aspirin or anticoagulants will mess up the test. The answer is nuanced. Low-dose aspirin (the kind people take for heart protection) does not meaningfully change FIT’s ability to spot cancer. One study found that continuous aspirin use left sensitivity, specificity, and overall diagnostic accuracy for colorectal cancer essentially unchanged.¹⁴ Separately, a case-control study concluded that the predictive value of a positive FIT for significant neoplasia was unaffected by ongoing anticoagulant or low-dose aspirin therapy, and recommended that these medications not be stopped before screening.¹⁵

However, the picture shifts slightly when you look across pooled data. A systematic review and meta-analysis found that aspirin, antiplatelet agents, and oral anticoagulants all lowered the positive predictive value of FIT for advanced colorectal neoplasia, meaning a higher proportion of positive results in users of these drugs turned out to be false alarms.¹⁶ In practical terms, the test still works for people on blood thinners. The main consequence is a somewhat higher chance of being sent for a colonoscopy that finds nothing dangerous. Most guidelines do not advise stopping these medications before a FIT.

Why Sample Handling Matters More Than You’d Think

Hemoglobin breaks down over time, especially in warmth. If your stool sample sits in a hot mailbox or on a counter for days, the hemoglobin can degrade enough that a truly positive sample reads as negative by the time it reaches the lab. Research has shown that in standard buffer solutions, hemoglobin concentration drops significantly after just three days of storage at temperatures above 35 degrees Celsius.¹⁷ At extreme conditions (50°C for 28 days, essentially a worst-case summer scenario), hemoglobin concentration in the standard buffer dropped to under 10 percent of its starting value.¹⁸

Newer buffer formulations improve stability. One reformulated buffer maintained hemoglobin above 80 percent of its original level for 20 days at room temperature, compared with only six days in the older version. Even at 35°C, the newer buffer held hemoglobin above 80 percent for eight days.¹⁹ The practical advice is simple: once you collect the sample, refrigerate it if possible and return it to the lab or mail it as soon as you can, ideally within a day or two. In warm climates, this is especially important.

When a Negative Result Doesn’t Mean Zero Risk

A negative FIT is reassuring, but it is not a guarantee. Cancers that appear between screening rounds, known as interval cancers, are a recognized limitation. In a study of over 485,000 participants who had a negative FIT, 544 interval cancers were detected within two years. The rate of interval cancer was lower when a stricter (lower) cutoff was used: about 9.5 per 10,000 persons versus nearly 14 per 10,000 with a higher cutoff.²⁰ A separate 13-year screening program found an interval cancer rate of about 1.87 per 10,000 person-years, with higher rates in the second year after the negative test, in proximal (right-sided) colon locations, and in older adults.²¹

Repeated negative results progressively lower your risk. A large study of over 133,000 individuals who initially tested negative found that the overall cancer incidence rate was 1.27 per 1,000 person-years, dropping by 63 percent after just one negative test. With repeated biennial negative results, the cumulative cancer risk over 10 years fell steadily, declining to roughly 10 percent of baseline risk after five consecutive negative rounds.²² This is the core argument for sticking to a regular screening schedule rather than treating one clean result as permanent clearance.

How Quickly You Need a Colonoscopy After a Positive FIT

If your FIT comes back positive, you need a follow-up colonoscopy. How fast that happens turns out to matter. A large study found no meaningful increase in the risk of being diagnosed with cancer or advanced-stage disease for colonoscopies done within six months of the positive result. But starting around seven to nine months, risk began to creep up, and by 10 to 12 months the increase was statistically significant.²³ A systematic review and meta-analysis confirmed that colonoscopies performed more than six months after a positive fecal test were linked to significantly higher odds of detecting colorectal cancer, advanced-stage cancer, and advanced adenomas compared to earlier follow-up. Shorter delays of one, two, or three months showed no meaningful difference from each other.²⁴ The practical message is that you don’t need to panic over a few weeks’ wait, but putting off the colonoscopy for more than half a year clearly increases the chance that a treatable problem becomes a harder one.

FIT Versus Newer Stool DNA Tests

A newer category of screening test combines FIT with molecular markers, detecting DNA mutations shed by tumors into stool. The first-generation multitarget stool DNA test (marketed as Cologuard) showed a cancer sensitivity of about 92 percent versus 74 percent for FIT, and caught about 42 percent of advanced precancerous lesions versus 24 percent with FIT. The trade-off was lower specificity: about 87 to 90 percent for the DNA test versus roughly 95 to 96 percent for FIT, meaning more false positives.²⁵

A next-generation version of the DNA test narrowed the gap further, reaching a cancer sensitivity of about 94 percent. A meta-analysis reported the next-generation test’s sensitivity for advanced precancerous lesions at roughly 46 percent, compared to about 22 percent for FIT, while the DNA test’s specificity came in around 92 percent versus 96 percent for FIT.²⁶ An interesting wrinkle emerged when researchers adjusted the FIT cutoff downward to match the DNA test’s specificity: at a lower threshold yielding about 91 percent specificity, FIT achieved 95 percent sensitivity for cancer, slightly edging out the DNA test, though still trailing for precancerous lesions.²⁷

Cost is another factor. FIT is inexpensive and can be done yearly, while the DNA test is more expensive and recommended every three years. FIT has been shown to be cheaper than colonoscopy for detecting advanced neoplasia and cancer in cost-effectiveness analyses.²⁸ The choice between FIT and stool DNA testing often comes down to cost, availability, and whether a person is more comfortable with a potentially higher false-positive rate in exchange for slightly better detection of precancerous growths.

Sex and Age Differences in Test Performance

FIT doesn’t perform identically in men and women. Research has consistently found that men have higher positivity rates and higher sensitivity for detecting advanced neoplasia, but also lower specificity, meaning more false positives. Women tend to have better specificity and a more reliable negative result. The upshot is that a negative FIT is less reassuring for ruling out advanced neoplasia in men than in women.²⁹ Age played a smaller role in raw sensitivity and specificity but affected predictive values because older people have a higher underlying prevalence of colorectal neoplasia. A systematic review concluded that more research is needed to establish whether sex- and age-specific cutoffs would improve the balance of harms and benefits.³⁰ Most screening programs currently use a single cutoff for everyone, though the evidence is building that a one-size-fits-all threshold may not be optimal.

Real-World Impact on Colorectal Cancer Deaths

The strongest argument for FIT screening is what happens at the population level. Taiwan’s national FIT screening program provided some of the most compelling data: individuals who actually completed screening had a 62 percent lower rate of death from colorectal cancer compared to those who did not. Even accounting for the fact that people who show up for screening tend to be healthier overall, the program’s 21 percent population coverage led to a statistically significant 10 percent reduction in colorectal cancer mortality across the board.³¹

Long-term follow-up data reinforce these findings. Comparing screened and unscreened populations, FIT screening cut the incidence of advanced-stage colorectal cancer by about a third and reduced colorectal cancer mortality by roughly 40 percent.³² A natural experiment across Italian provinces found that regions implementing organized FIT screening saw an initial bump in detected cases (the expected catch-up effect as prevalent cancers are found), followed by a nearly 9 percent reduction in colorectal cancer death rates after seven years.³³

These mortality reductions are driven by stage shift: FIT catches cancers earlier, when surgery alone can often cure them, rather than at advanced stages requiring chemotherapy with worse outcomes. The test isn’t perfect, and it misses a meaningful share of precancerous polyps on any single use. But its low cost, ease of use, high participation rates, and strong track record in repeated screening rounds make it the backbone of colorectal cancer screening in most of the world’s organized programs.